Primary Immune Thrombocytopenia
Study code: 20-003
People with Primary Immune Thrombocytopenia needed for the study of a potential new medicine for treating ITP. You must be aged 18 to 55 and must have been diagnosed at least 3 months ago. The study involves 2 screening visits, 8 nights’ residence and 7 outpatient visits over approximately 2 and a half months.